Ovison kutanopløsning

Ovison is a pharmaceutical product used for treating skin conditions, containing the active ingredient mometasone furoate. It is specifically formulated as a cutaneous solution for topical application. The brand is part of the portfolio of Galderma, a global leader in dermatological treatments.

Originally established as a joint venture between Nestlé and L'Oréal, Galderma transitioned to private ownership in 2019 under an investment group led by EQT. The product is distributed across Europe, including Denmark, and manufacturing typically occurs in specialized pharmaceutical facilities located primarily in France and Germany, though global sourcing can vary.